非小细胞肺癌治疗的新进展
查看参考文献20篇
|
文摘
|
原发性支气管肺癌是当前世界上最常见的恶性肿瘤,且肺癌的发病率和病死率在全世界范围内有逐年增高的趋势。几乎所有国家中,肺癌的男性患者数量均多于女性,并随年龄的增长而逐渐升高。在肺癌的发生率相关危险因素中,烟草的流行尤为显著相关,工业化的发展及环境的恶化也是肺癌发生的相关危险因素。近年来肺癌的诊断手段及治疗方式取得了很大进步,肺癌的检查技术由X线检查发展到肺部增强CT、正电子发射计算机断层显像(positron emission computed tomography,PET) / CT、气管镜技术等,大大提高了早期诊断率。外科手术治疗肺癌进入到微创胸外科时代,肺癌的化疗药物也发展到第四代,一大批分子靶向应用于临床药物并取得显著疗效。但遗憾的是,肺癌的治疗现状不容乐观,总的5年生存率仍在10%左右。本文将对非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗现状及进展进行综述。 |
|
来源
|
中华危重症医学杂志(电子版)
,2017,10(6):416-420 【扩展库】
|
|
DOI
|
10.3877/cma.j.issn.1674-6880.2017.06.013
|
|
关键词
|
非小细胞
;
肺癌治疗
;
恶性肿瘤
|
|
地址
|
浙江大学医学院附属第一医院老年病科, 杭州, 310003
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1674-6880 |
|
学科
|
肿瘤学 |
|
基金
|
国家临床重点专科建设项目
;
浙江省医药卫生科技计划项目
|
|
文献收藏号
|
CSCD:6180542
|
参考文献 共
20
共1页
|
|
1.
Ettinger D S. Non-small cell lung cancer.
Natl Compr Cancer Net,2010(7):740-801
|
CSCD被引
1
次
|
|
|
|
|
2.
Delbaldo C. WITHDRAWN: second or third additional chemotherapy drug for nonsmall cell lung cancer in patients with advanced disease.
Cochrane Database Syst Rev,2012(4):CD004569
|
CSCD被引
2
次
|
|
|
|
|
3.
Cappuzzo F. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol,2010,11(6):521-529
|
CSCD被引
59
次
|
|
|
|
|
4.
Sequist L. PhaseⅢstudy of aftinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with epidermal growth factor receptor mutations.
J Clin Oncol,2013,31(27):3327-3334
|
CSCD被引
2
次
|
|
|
|
|
5.
Wu Y L. LUX-Lung 6: a randomized, open-label, phaseⅢstudy of afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive(EGFR M+) advanced adenocarcinoma of the lung.
Eur Resp J,2013,42:371
|
CSCD被引
1
次
|
|
|
|
|
6.
Yang J. LBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790Mpositive advanced NSCLC: updated phase 1 (P1) and pooled phase 2 (P2) results.
J Thorac Oncol,2016,11(4 Suppl):S152-S153
|
CSCD被引
8
次
|
|
|
|
|
7.
Karlovich C. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686).
Clin Cancer Res,2016,22(10):2386-2395
|
CSCD被引
7
次
|
|
|
|
|
8.
Priker R. Cetuximab plus chemotherapy in patient with advanced non-smallcell lung cancer (FLEX): an open-label randomized phaseⅢtrial.
Lancet,2009,373(9674):1525-1531
|
CSCD被引
56
次
|
|
|
|
|
9.
Kwak E L. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med,2010,363(18):1693-1703
|
CSCD被引
126
次
|
|
|
|
|
10.
Shaw A T. Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med,2014,370(13):1189-1197
|
CSCD被引
42
次
|
|
|
|
|
11.
Gridelli C. BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer.
Clin Lung Cancer,2016,17(5):461-465
|
CSCD被引
3
次
|
|
|
|
|
12.
Kozuki T. Feasibility study of first-line chemotherapy using pemetrexed and bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
BMC Cancer,2016,16:306
|
CSCD被引
1
次
|
|
|
|
|
13.
Garon E B. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet,2014,384(9944):665-673
|
CSCD被引
37
次
|
|
|
|
|
14.
Brahmer J. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer.
N Engl J Med,2015,373(2):123-135
|
CSCD被引
295
次
|
|
|
|
|
15.
Gatzemeier U. Randomized phaseⅡtrial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Ann Oncol,2004,15(1):19-27
|
CSCD被引
15
次
|
|
|
|
|
16.
Paz-Ares L. MISSION triala phaseⅢ, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.
J Thorac Oncol,2015,10(12):1745
|
CSCD被引
4
次
|
|
|
|
|
17.
Hainsworth J D. A phaseⅡ, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
J Thorac Oncol,2010,5(10):1630
|
CSCD被引
4
次
|
|
|
|
|
18.
Ohe Y. Chemoradiotherapy for lung cancer current status and perspective.
Int J Clin Oncol,2004,9(6):435-443
|
CSCD被引
4
次
|
|
|
|
|
19.
Sayed M M. Definitive chemoradiation for non-small-cell lung cancer: could a consensus be reached?.
Tumori,2016,102(5):496-500
|
CSCD被引
1
次
|
|
|
|
|
20.
王劲. 生活方式的改进与安全社区的构建.
中华危重症医学杂志(电子版),2013,6(3):132-133
|
CSCD被引
1
次
|
|
|
|
|
了解气象卫星更多信息，请访问